- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway ; day:2 ; month:2 ; year:2018 ; pages:1-11
PharmacoEconomics ; (2.2.2018), 1-11
- Creator
-
Wisløff, Torbjørn
- Contributor
-
White, Richard
Dalgard, Olav
Amundsen, Ellen J.
Meijerink, Hinta
Løvlie, Astrid Louise
Kløvstad, Hilde
SpringerLink (Online service)
- DOI
-
10.1007/s40273-017-0604-3
- URN
-
urn:nbn:de:1111-201803302447
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wisløff, Torbjørn
- White, Richard
- Dalgard, Olav
- Amundsen, Ellen J.
- Meijerink, Hinta
- Løvlie, Astrid Louise
- Kløvstad, Hilde
- SpringerLink (Online service)
Other Objects (12)
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study
Hepatitis C clearance by direct-acting antivirals impacts glucose and lipid homeostasis
Direct-acting antivirals and visceral leishmaniasis: a case report
Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications
Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease
Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era
Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study